Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation

Molecular Cancer Therapeutics

Volumn 11, Issue 5, 2012, Pages 1051-1061

  Bitterman, Peter B ^a,b   Polunovsky, Vitaly A ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAP BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN; INITIATION FACTOR 4F; MESSENGER RNA;

CANCER CELL; CANCER THERAPY; DRUG DEVELOPMENT; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION INITIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; EUKARYOTIC INITIATION FACTOR-4F; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION;

EID: 84862741954     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0530     Document Type: Review

References (75)

1. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7. (Pubitemid 39551656)
2. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700. (Pubitemid 44764211)
3. Jänne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009;8:709-23.
4. Raguz S, Yagüe E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 2008;99:387-91.
5. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99. (Pubitemid 39070849)
6. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011;331:1553-8.
7. Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008;14:6277-83.
8. Polunovsky VA, Bitterman PB. The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol 2006;3: 10-7.
9. Foulds L. The experimental study of tumor progression: a review. Cancer Res 1954;14:327-39.
10. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139-46. (Pubitemid 23161701)
11. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-4. (Pubitemid 34743088)
12. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011;145:30-8.
13. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther 2010;9:3137-44.
14. Bitterman P, Polunovsky VA. Translational control of cancer: Implications for targeted therapy. In:Polunovsky VA, Houghton P, editors. mTOR pathway and mTOR inhibitors in cancer therapy. New York: Springer/Humana Press; 2010. p. 237-55.
15. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010;10:254-66.
16. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009;136:731-45.
17. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
18. Joshi B, Cai AL, Keiper BD, Minich WB, Mendez R, Beach CM, et al. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem 1995;270:14597-603.
19. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 1999;19:1871-80. (Pubitemid 29098245)
20. Ruggero D. The role of Myc-induced protein synthesis in cancer. Cancer Res 2009;69:8839-43.
21. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-99. (Pubitemid 38638830)
22. Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, Smith K, et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 2007;67:6814-24. (Pubitemid 47105529)
23. Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2007;2:e242.
24. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res 2010;16:4914-20.
25. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484-6. (Pubitemid 38667906)
26. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5¢cap. Nature 1990;345:544-7.
27. Kim YY, Von Weymarn L, Larsson O, Fan D, Underwood JM, Peterson MS, et al. Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res 2009;69:8455-62.
28. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-63. (Pubitemid 38748917)
29. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008;118:2651-60. (Pubitemid 351949792)
30. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-48. (Pubitemid 47494364)
31. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007;128:257-67. (Pubitemid 46137991)
32. Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR, Sun SY. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther 2009;8:1463-9.
33. Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 2004;64:8639-42. (Pubitemid 39552077)
34. Koromilas AE, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 5¢ non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J 1992;11:4153-8.
35. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenicmTORpathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010;17:249-61.
36. Mavrakis KJ, Wendel HG. Translational control and cancer therapy. Cell Cycle 2008;7:2791-4.
37. Pelletier J, Graff JR. Downstream from mTOR: Theraputic approachs to targeting the eIF4E translation initiation complex. In:Polunovsky VA, Houghton P, editors. mTOR pathway and mTOR inhibitors in cancer therapy. New York: Springer/Humana Press; 2010. p. 257-285.
38. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
39. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010;16:3094-9.
40. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12. (Pubitemid 350145909)
41. Lin CJ, Robert F, Sukarieh R, Michnick S, Pelletier J. The anti-depressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling. Cancer Res 2010;70:3199-208.
42. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8. (Pubitemid 43259931)
43. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74.
44. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression ofmRNAtranslation. Proc Natl Acad SciUSA 2008;105:17414-9.
45. Downward J. Targeting RAF: trials and tribulations. Nat Med 2011;17:286-8.
46. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21:3232-7. (Pubitemid 350277750)
47. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 2011;71:1849-57.
48. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4EBP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39-51.
49. Fan S, Li Y, Yue P, Khuri FR, Sun SY. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation. Neoplasia 2010;12:346-56.
50. Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A 2011;108:1046-51.
51. Low WK, Dang Y, Schneider-Poetsch T, Shi Z, Choi NS, Merrick WC, et al. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol Cell 2005;20:709-22. (Pubitemid 41740693)
52. Korneeva NL. Translational dysregulation by pateamine A. Chem Biol 2007;14:5-7. (Pubitemid 46124071)
53. Kim S, Hwang BY, Su BN, Chai H, Mi Q, Kinghorn AD, et al. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res 2007;27[4B]:2175-83. (Pubitemid 47228051)
54. Hong DS, Kurzrock R, Oh Y, Wheler JJ, Naing A, Brail L, et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 2011;17:6582-91.
55. Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 2011;17:2874-84.
56. Westman B, Beeren L,Grudzien E, Stepinski J,Worch R, Zuberek J, et al. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. RNA 2005;11:1505-13. (Pubitemid 41396920)
57. Yan Y, Svitkin Y, Lee JM, Bisaillon M, Pelletier J. Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA 2005;11:1238-44. (Pubitemid 41132395)
58. Ghosh P, Park C, Peterson MS, Bitterman PB, Polunovsky VA, Wagner CR. Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP. Bioorg Med Chem Lett 2005;15:2177-80. (Pubitemid 40445489)
59. Grudzien E, Stepinski J, Jankowska-Anyszka M, Stolarski R, Darzynkiewicz E, Rhoads RE. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 2004;10:1479-87. (Pubitemid 39122118)
60. Ghosh B, Benyumov AO, Ghosh P, Jia Y, Avdulov S, Dahlberg PS, et al. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol 2009;4:367-77.
61. Wagner CR, Chang SL, Griesgraber GW, Song H, McIntee EJ, Zimmerman CL. Antiviral nucleoside drug delivery via amino acid phosphoramidates. Nucleosides Nucleotides 1999;18:913-9. (Pubitemid 29320629)
62. Chou TF, Baraniak J, Kaczmarek R, Zhou X, Cheng J, Ghosh B, et al. Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins. Mol Pharm 2007;4:208-17. (Pubitemid 46640597)
63. Jia Y, Chiu TL, Amin EA, Polunovsky V, Bitterman PB, Wagner CR. Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP. Eur J Med Chem 2010;45:1304-13.
64. Borok Z, Whitsett JA, Bitterman PB, Thannickal VJ, Kotton DN, Reynolds SD, et al. Cell plasticity in lung injury and repair: report from an NHLBI workshop, April 19-20, 2010. Proc Am Thorac Soc 2011;8:215-22.
65. Rajasekhar VK, Holland EC. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene 2004;23:3248-64. (Pubitemid 38638836)
66. Larsson O, Bitterman PV. Genome-wide analysis of translational control. In:Polunovsky VA, Houghton P, editors. mTOR pathway and mTOR inhibitors in cancer therapy. New York: Springer/Humana Press; 2010. p. 217-36.
67. Provenzani A, Fronza R, Loreni F, Pascale A, Amadio M, Quattrone A. Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. Carcinogenesis 2006;27:1323-33. (Pubitemid 43985407)
68. Gunnery S,Mäivali U, MathewsMB. Translation of an uncapped mRNA involves scanning. J Biol Chem 1997;272:21642-6. (Pubitemid 27374042)
69. Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, Nawas S, et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 2002;235:732-8; discussion 738-9.
70. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, et al. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 2008;7:1782-8.
71. Zindy P, Bergé Y, Allal B, Filleron T, Pierredon S, Cammas A, et al. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res 2011;71:4068-73.
72. Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res 2010;34:535-41.
73. Jacobson BA, Alter MD, Kratzke MG, Frizelle SP, Zhang Y, Peterson MS, et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 2006;66:4256-62.
74. Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol 2008;28:6496-509.
75. Zhao JJ, Roberts TM, Hahn WC. Functional genetics and experimental models of human cancer. Trends Mol Med 2004;10:344-50. (Pubitemid 38881524)